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Abstract
Background: The biological mechanisms of headache chronification are poorly understood. We aimed to identify
changes in DNA methylation associated with the transformation from episodic to chronic headache.
Methods: Participants were recruited from the population-based Norwegian HUNT Study. Thirty-six female headache
patients who transformed from episodic to chronic headache between baseline and follow-up 11 years later were
matched against 35 controls with episodic headache. DNA methylation was quantified at 485,000 CpG sites, and changes
in methylation level at these sites were compared between cases and controls by linear regression analysis. Data were
analyzed in two stages (Stages 1 and 2) and in a combined meta-analysis.
Results: None of the top 20 CpG sites identified in Stage 1 replicated in Stage 2 after multiple testing correction. In the
combined meta-analysis the strongest associated CpG sites were related to SH2D5 and NPTX2, two brain-expressed
genes involved in the regulation of synaptic plasticity. Functional enrichment analysis pointed to processes including
calcium ion binding and estrogen receptor pathways.
Conclusion: In this first genome-wide study of DNA methylation in headache chronification several potentially
implicated loci and processes were identified. The study exemplifies the use of prospectively collected population
cohorts to search for epigenetic mechanisms of disease.
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In a number of patients who suffer from episodic head-
ache attacks, their headache transforms into a chronic
form (1,2). Chronic headache, defined as headache
occurring on at least 15 days per month, affects 3–5%
of the general population and 40% of patients in head-
ache clinics, and is associated with severe disability and
impaired quality of life (1,3). Approximately half of
these patients have chronic migraine (1). Established
risk factors for headache chronification include the
overuse of acute headache medications and a high base-
line attack frequency (4). The biological mechanisms
involved in the transition from episodic to chronic
headache are, however, unknown.
In recent years it has become evident that epigenetic
processes play an important role in a range of multifac-
torial diseases (5). Epigenetics entail changes in gene
expression that are not due to variation in the DNA
sequence. A main epigenetic mechanism is DNA
methylation, the covalent addition of a methyl group
to the 5th carbon of cytosine residues, which is typically
associated with gene silencing (5,6). Epigenetic modifi-
cations can be stably inherited through cell divisions
but can also be dynamic. They enable cell and develop-
mental stage-specific regulation of gene expression, and
play an important role in programming lasting
responses to environmental cues (6,7). Due to the ability
of DNA methylation changes to shift a biological system
from one stable state to another, their implication in
headache chronification is of particular interest. It has
been hypothesized that frequent headache attacks may
lower the threshold for subsequent headache attacks
through epigenetic mechanisms resulting in a feed-for-
ward loop (6). Similarly, psychological stress and female
sex hormones, which have been implicated in migraine
genesis, are known to exert their physiological effects
partly through epigenetic mechanisms (6,8).
In this study, subjects were recruited from the
Norwegian population-based Nord-Trøndelag Health
(HUNT) Study, where they gave blood samples and
were assessed for headache at two time points 11
years apart. In order to identify changes in DNA
methylation associated with headache chronification
we compared cases who transformed from episodic to
chronic headache during the follow-up period with con-
trols who did not develop chronic headache. For all
selected subjects, genome-wide DNA methylation
levels were characterized at baseline and follow-up.
Materials and methods
Participants
In the HUNT2 (1995–1997) and HUNT3 (2006–2008)
studies, the entire population of the Norwegian county
of Nord-Trøndelag, 20 years of age or older, was
invited to complete extensive questionnaires con-
cerning health-related issues, participate in a clinical
examination and donate blood samples. Among
92,566 individuals in HUNT2 and 94,194 in HUNT3
invited to participate, 51,383 (56%) and 39,701
(42%), respectively, answered the headache ques-
tionnaire (9,10).
The headache classification used in this study has
been described in detail elsewhere (9–11). Briefly, in
each survey those who answered ‘yes’ to the screening
question ‘Have you suffered from headache during the
last year?’ were defined as headache sufferers and asked
to fill in the other headache questions. Participants indi-
cated the number of days with headache per month,
with the options <7, 7–14 or >14 days/month in
HUNT2 and the options <1, 1–6, 7–14 or >14 days/
month in HUNT3. Chronic daily headache (CDH) was
defined as headache occurring on 15 days/month. In
HUNT2, acute medication overuse was defined as
‘analgesic use daily or almost daily for 1 month
during the last 12 months’, and in HUNT3 as ‘over-
the-counter-medication use for headache 4 days/week
during the last month’. Medication-overuse headache
was defined as the combination of CDH and acute
medication overuse (9,11,12). This headache classifica-
tion has been validated by interview diagnoses (9,10).
In HUNT2, the sensitivity and specificity were, respect-
ively 85% and 83% for headache suffering (Cohen’s
kappa k¼ 0.57), and 91% and 56% for headache fre-
quency <7 days per month (k¼ 0.50). In HUNT3, the
sensitivity and specificity were, respectively 88% and
86% for headache suffering (k¼ 0.70), 69% and 99%
for CDH (k¼ 0.75) and 75% and 100% for medica-
tion-overuse headache (k¼ 0.75).
Cases for the current study were selected among par-
ticipating women who at the time of HUNT2 (baseline)
were 35 years of age and reported headache on <7
days/month, and at the time of HUNT3 (follow-up)
reported 15 headache days/month (CDH). To avoid
sample heterogeneity resulting from different DNA
methylation patterns in men and women, only women
were included. Likewise, to avoid DNA methylation
changes resulting from the onset of menopause during
follow-up only women 35 years of age at baseline
were included. In total 43 subjects fulfilled these cri-
teria. After excluding samples with missing DNA
from either baseline or follow-up, 40 cases were
included in the study. We selected an equal number
of controls, who were matched with cases on their
headache frequency and age at baseline, but at
follow-up either did not have headache anymore or
had headache on <7 days/month. Average time
between baseline and follow-up examinations was
11.4 years (range 10–12.6 years).
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Ethics
Signed informed consent was obtained from all partici-
pants in the HUNT2 and HUNT3 surveys, and the
present study was approved by the Regional
Committee for Medical Research Ethics (2012/2316/
REK midt).
Genome-wide quantification of DNA methylation
A detailed description of sample handling, quantifica-
tion of DNA methylation, data normalization and
quality control is given in Supplemental Methods.
Briefly, we performed array quantification of DNA
methylation on genomic DNA isolated from leuko-
cytes, after bisulfite conversion, using the Illumina
Infinium HumanMethylation450 BeadChip (Illumina,
San Diego, CA, USA). For Stage 1, 96 samples from
24 cases and 24 controls were analyzed. For Stage 2, 64
samples from 16 cases and 16 controls were analyzed.
The methylation level at each CpG site for each sample
was calculated as a b-value, scaling from 0 (not methy-
lated) to 1 (fully methylated). After sample-wise quality
control steps, 36 cases and 35 controls contributed to
the final analysis. An overview of the study design and
participants in the final analysis are given in Figure 1.
After marker-wise quality control steps, out of 485,775
CpG markers initially interrogated 431,282 and 436,517
markers were available for analysis in Stage 1 and Stage
2, respectively. No differences in estimated white blood
cell ratios were found between patients and controls for
Stage 1, nor for Stage 2 (Supplemental Tables 2 and 3,
and Supplemental Methods), therefore we did not
include the ratios as cofactors in the analysis.
Analytic approach
Baseline characteristics. Baseline characteristics were
compared between cases and controls by Fisher’s
exact test (for binary variables) or independent samples
t-test (for continuous variables). The examined vari-
ables included known or suggested risk factors for the
development of chronic daily headache (4,13); age (con-
tinuous); low educational level (upper secondary school
or less as highest education); self-reported daily use of
tranquilizers last year (yes, no); current daily smoking
(yes, no); low physical activity (<1 hour light exercise
per week); body-mass index (continuous); Hospital
Anxiety and Depression Scale (HADS) for each of anx-
iety and depression (continuous) (14), chronic muscu-
loskeletal complaints (yes, no) (15); gastrointestinal
complaints (yes, no) (16), self-reported diabetes mellitus
(yes, no) and self-reported rheumatoid or osteoarthritis
(yes, no). Of the participants included in the study, 3
had missing information on physical activity and 1 on
chronic musculoskeletal complaints.
Association analysis and replication. The effect of headache
chronification (case-control status) was modeled on
changes in DNA methylation levels. For each individ-
ual, normalized methylation level estimate (b-value) at
baseline was subtracted from methylation level estimate
at follow-up for each CpG site. Resulting methylation
level changes at each CpG site were then compared
between cases and controls using linear regression
model adjusted for age, using the lm package in R soft-
ware (17). Data from each stage was analyzed separ-
ately and the 20 CpG sites showing strongest
association with chronification in Stage 1 were taken
Baseline
Cases
Stage 1: n = 23
Stage 2: n = 13
Total: n = 36
Controls
Stage 1: n = 21
Stage 2: n = 14















Figure 1. Diagram of the study design and participants. A total of 36 female headache patients who transformed from episodic to
chronic headache (‘cases’) between examinations at baseline and follow-up were matched against 35 female headache patients who did
not transform to chronic headache (‘controls’).
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forward for replication in Stage 2. A Bonferroni-cor-
rected p-value threshold (0.05/20¼ 0.0025) was used to
consider statistically significant replication.
Meta-analysis. Subsequently, a fixed-effects meta-analy-
sis was performed on DNA methylation data from
Stage 1 and Stage 2, weighted by the inverse variance,
using the GWAMA software (18). In total 436,549
CpG markers were present in either stage after quality
control and could be used in the analysis, resulting in a
Bonferroni-corrected p-value threshold of 1.15 107
(0.05/436,549).
Characterization of top-ranking CpG sites. Functional pro-
filing of the meta-analysis top-ranking CpG sites was
carried out using g:Profiler web-based software (19), see
Supplemental Methods for a full description. Briefly,
g:Profiler performs a statistical gene set enrichment
analysis to find functional gene groups or biological
pathways that are significantly over-represented in
user-provided input. The results presented are based
on the 200 top-ranking CpG sites from the meta-
analysis, and results were considered significant if the
multiple testing corrected p-value for the enriched
group or pathway was .05. Characterization of gene
expression in various human tissues was retrieved from
the GTEx database (20). Although DNA methylation is
largely tissue-specific, inter-individual variation in
DNA methylation has been shown to correlate between
blood and brain for a subset of CpG sites (21).
Correlation of DNA methylation levels between
blood and brain at the top CpG sites was analyzed
using the Blood Brain DNA Methylation Comparison
tool (http://epigenetics.essex.ac.uk/bloodbrain) that
utilizes DNA methylation data of blood and four dif-
ferent brain regions from matched samples (21).
Analysis of medication overuse. Overuse of acute headache
medications is a known risk factor for headache chron-
ification. To evaluate to what extent medication overuse
influenced the identified associations, the association
analysis and meta-analysis was repeated stratified by
medication overuse. Cases with or without medication
overuse at follow-up were analyzed separately against all
controls. Results were visualized as forest plots using the
metafor R package (version 1.9-8) (22). Additionally,
unsupervised clustering of the samples was performed
using the hclust R package, based on their methylation
levels at follow-up at each of the 200 top-ranking CpG
sites from the initial meta-analysis.
Results
Demographic variables and potential risk factors for
CDH did not differ between cases and controls at
baseline (Table 1). However, four participants reported
medication overuse at baseline, and all four later devel-
oped CDH. Likewise no difference between cases and
controls was found for the listed variables when Stage 1
and Stage 2 were analyzed separately (data not shown).
Average time between baseline and follow-up examin-
ations was 11.4 years (range 10–12.6 years). At the time
of follow-up 17 of 36 cases (47%) and 0 of 35 controls
reported overuse of acute headache medication.
The 20 CpG sites that demonstrated the strongest
association with headache chronification in Stage 1
are listed in Table 2. Using the Bonferroni-corrected
statistical significance level of 0.0025, none of these
CpG sites reached statistical significance for replication
in Stage 2. When data from the two stages were com-
bined in a fixed-effects meta-analysis, no CpG sites
reached the multiple-testing corrected study-wide sig-
nificance threshold of 1.15 107. The most strongly
associated CpG marker was cg01010870 (p-value¼
6.17 106), located near the transcription start site
of the gene SH2D5 (Table 3) that is highly expressed
in various regions of the human brain (Supplemental
Figure 1). The second most strongly associated
CpG marker cg11086695 (p-value¼ 6.95 106) is
intergenic, located 76 kb downstream from NPTX2
Table 1. Demographic and clinical characteristics at baseline





Age (mean [SE]) 26.1 [0.71] 26.3 [0.76] 0.85a
Higher education (n, [%]) 6 [17.1] 10 [27.8] 0.40b
Acute medication
overuse (n, [%])
0 [0] 4 [11.1] 0.12b
Daily use of
tranquilizers (n, [%])
0 [0] 0 [0] n.a.
Daily smoking (n, [%]) 9 [25.7] 10 [27.8] 1.0b
Low physical
activity (n, [%])
22 [66.7] 20 [57.1] 0.46b
Body-mass index
(mean [SE])
25.9 [0.70] 25.2 [0.68] 0.44a
HADS Anxiety score
(mean [SE])
4.20 [0.52] 5.28 [0.64] 0.20a
HADS Depression score
(mean [SE])
2.46 [0.37] 2.51 [0.51] 0.94a
Chronic musculoskeletal
complaints (n, [%])
9 [25.7] 16 [45.7] 0.13b
Gastrointestinal
complaints (n, [%])
22 [62.9] 25 [69.4] 0.62b
Diabetes mellitus (n, [%]) 0 [0] 1 [2.8] 1.0b
Arthritis (n, [%]) 0 [0] 1 [2.8] 1.0b
n.a.¼ not applicable.
aIndependent samples t-test. bFisher’s exact test.
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and 141 kb downstream from TMEM130. For 6 of
the top 10 CpG markers (Table 3), methylation levels
in blood showed high correlation with methylation
levels in one or several regions of the human brain at
p-value< .05 (21), exemplified for the most significantly
associated CpG site (cg01010870) in Figure 2.
Genomic regions corresponding to the 200 top-
ranking CpG sites from the meta-analysis were
Table 2. Summary statistics of the 20 CpG sites that showed strongest association with headache chronification in Stage 1.
Discovery (Stage 1) Replication (Stage 2)
Marker Chr Position Gene(s)* b SE p b SE p
cg00113321 7 157737485 PTPRN2 0.031 0.0054 1.17E-06 0.003 0.0112 0.79
cg01010870 1 20732775 SH2D5 0.022 0.0041 3.93E-06 0.009 0.0077 0.27
cg20968963 2 2767914 MYT1L; LINC01250 0.021 0.0040 4.41E-06 0.000 0.0077 0.99
cg07195851 5 3517408 LINC01019 0.039 0.0075 5.17E-06 0.003 0.0123 0.78
cg18321073 5 12795593 LINC01194 0.033 0.0063 7.17E-06 0.012 0.0110 0.29
cg18221862 2 192194504 TMEFF2 0.019 0.0038 8.58E-06 0.009 0.0058 0.13
cg12614711 7 1496305 INTS1 0.011 0.0022 8.98E-06 0.012 0.0042 0.007
cg13432241 4 153468133 KIAA0922 0.016 0.0032 1.25E-05 0.005 0.0043 0.21
cg03091590 19 42196421 POU2F2 0.023 0.0047 2.14E-05 0.005 0.0087 0.56
cg24993607 13 112602844 RP11-88E10.4 0.023 0.0049 2.25E-05 0.001 0.0072 0.92
cg14006774 19 44676311 CEACAM19 0.027 0.0059 3.81E-05 0.003 0.0102 0.79
cg15127702 7 101436336 COL26A1 0.048 0.0104 3.97E-05 0.008 0.0176 0.65
cg17509967 19 13506280 CACNA1A 0.011 0.0025 3.99E-05 0.004 0.0063 0.53
cg26835520 16 32253720 TP53TG3D 0.022 0.0049 4.90E-05 0.002 0.0050 0.69
cg24281422 8 67064238 COPS5; CSPP1 0.014 0.0030 5.03E-05 0.010 0.0069 0.16
cg08231664 14 102050295 DYNC1H1 0.023 0.0050 5.38E-05 0.012 0.0065 0.08
cg20137441 12 132553440 FBRSL1 0.023 0.0051 5.52E-05 0.003 0.0061 0.58
cg26764019 19 2462520 LOC101928602;
GADD45B
0.016 0.0036 6.08E-05 0.003 0.0061 0.67
cg04388053 X 153904893 AVPR2 0.021 0.0048 6.49E-05 0.013 0.0062 0.04
cg14209854 16 11276493 RMI2 0.022 0.0050 6.52E-05 0.004 0.0078 0.63
b, SE (standard error) and p (p-value) for association between headache chronification and change in CpG site methylation (linear regression model),
adjusted for age. Chr¼ chromosome. Position¼ genome position (build GRCh38). *For probes not located in direct relation to a gene, the two
nearest genes are listed, separated by semicolon.
Table 3. CpG loci demonstrating strongest association to headache chronification in combined meta-analysis.
Marker Chr Position Gene** b SE p b (Stage 1) b (Stage 2)
cg01010870* 1 20732775 SH2D5 0.018 0.0041 6.17E-06 0.022 0.009
cg11086695* 7 98705889 NPTX2; TMEM130 0.039 0.0086 6.95E-06 0.038 0.041
cg00113321* 7 157737485 PTPRN2 0.024 0.0055 1.23E-05 0.031 0.003
cg18321073 5 12795593 LINC01194 0.026 0.0061 1.41E-05 0.033 0.012
cg02969243* X 11427642 ARHGAP6 0.027 0.0062 1.50E-05 0.028 0.024
cg05678960* Y 6265797 TSPY2; LINC00280 0.056 0.0130 1.89E-05 0.054 0.078
cg13952745 4 92304315 GRID2 0.016 0.0038 1.91E-05 0.016 0.016
cg20458019* 4 2275622 ZFYVE28 0.015 0.0036 2.30E-05 0.015 0.015
cg23174760 1 63150382 RP11-335E6.2 0.022 0.0052 2.51E-05 0.024 0.019
cg14118171 9 131475765 PRRC2B 0.014 0.0033 2.70E-05 0.012 0.016
*Methylation levels in blood showing high correlation with methylation levels in one or more regions of the human brain at p-value< .05. **For CpG
markers not located in direct relation to a gene, the two nearest genes are listed. b, SE (standard error) and p (p-value) for association between
headache chronification and change in CpG site methylation in meta-analysis of results from Stages 1 and 2. Chr¼ chromosome. Position¼ genome
position (build GRCh38).
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significantly enriched for genes belonging to specific
biological functions (Table 4, Supplemental Table 1).
Statistically strongest enrichment was observed for ‘cal-
cium ion binding’ (p-value¼ 1.21 105), followed by
‘biological adhesion’ (p-value¼ 4.23 105), ‘intracel-
lular estrogen receptor signaling’ (p-value¼ 0.02), and
‘negative regulation of homotypic cell-cell adhesion’
(p-value¼ .04).
When stratifying the meta-analysis for overuse of
acute headache medications among cases, the associ-
ations for the 10 top-ranking CpG sites from the initial
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Figure 2. Correlation of DNA methylation in blood and four brain regions for cg01010870 (SH2D5). Top: Boxplot of the
distribution of DNA methylation values for cg01010870 split by tissue. Bottom: Four scatterplots demonstrating the relationship
between DNA methylation in whole blood and four brain regions: PFC¼ pre-frontal cortex; EC¼ entorhinal cortex; STG¼ superior
temporal gyrus; CER¼ cerebellum. Plots are retrieved using the Blood Brain DNA Methylation Comparison tool (21).
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comparable strength in each of the two groups
(Figure 3). Likewise, unbiased hierarchical cluster ana-
lysis based on the 200 top-ranking CpG sites did not
discriminate between cases with and without medica-
tion overuse (Figure 4).
Discussion
This is, to our knowledge, the first study of epigenetic
changes in headache chronification. Using a retrospect-
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Figure 3. Forest plots showing meta-analysis results separately for cases with and without medication overuse. Meta-analysis
beta-value (Beta) and its 95% confidence intervals (95% CI) for the top 10 CpG sites (cg01010870 to cg14118171) from the
meta-analysis.
Table 4. Functional profiling of top associated CpG sites and corresponding genes.
p-value* Term ID Term name
1.21E-05 GO:0005509 calcium ion binding
4.23E-05 GO:0022610 biological adhesion
3.87E-05 GO:0007155 cell adhesion
7.21E-06 GO:0098609 cell-cell adhesion
6.52E-10 GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
6.68E-12 GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
0.024 GO:0030520 intracellular estrogen receptor signaling pathway
0.037 GO:0034111 negative regulation of homotypic cell-cell adhesion
*Functional profiling using g:Profiler. The p-values are corrected for multiple testing. Highest-level hierarchical groups and pathways (‘main terms’) that
were significant are marked in bold. Increased indent indicates deeper level in the local hierarchy under the group or pathway.
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were examined across the genome comparing patients
who converted from episodic to chronic headache
during an 11-year follow-up period with matched con-
trols. In the discovery stage several CpG sites showed
suggestive association to headache chronification, but
these failed to replicate in the second stage. Combining
association results from both stages in a fixed-effects
meta-analysis we identified CpG sites that may point
to genes involved in headache chronification. An
enrichment was found for genes related to calcium
ion binding, biological adhesion, and intracellular
estrogen receptor signaling.
Since cases in this study reported episodic headache
at baseline and CDH at the time of follow-up, it is
likely that they represent transformed rather than
de-novo chronic headache. However, a limitation is
that the questionnaire-based assessment did not allow
distinction of chronic migraine from other types of
chronic headache. Previous epidemiological studies
suggest that approximately half of those with CDH
fulfill criteria for chronic migraine (1), making it
likely that migraineurs contribute substantially to our
case group.
Medication overuse is a major risk factor for head-
ache chronification, and it has previously been shown
that medication overuse headache accounts for about
half of the participants who report CDH in the HUNT
population (13). A similar proportion was seen in this
study with 17 of 36 cases (47%), but none of the con-
trols, reporting medication overuse at the time of
follow-up. Notably, all 4 participants who reported
medication overuse at baseline had developed chronic
headache at follow-up. Given our design, it is feasible
that at least some of the DNA methylation changes
result from medication use. Still, when stratifying the
meta-analysis results by cases with and without medi-
cation overuse, the strength and direction of associ-
ation for the top 10 loci from the meta-analysis were
similar between the groups (Figure 3). Also, unsuper-






























































































































































































Figure 4. Unsupervised clustering of cases based on the top 200 CpG sites from the meta-analysis. Unsupervised hierarchical
clustering using methylation status at follow-up did not discriminate between cases with (marked in yellow) and without medication
overuse in either Stage 1 (A) or Stage 2 (B).
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methylation levels for the top 200 CpG sites did not
discriminate cases with from cases without medication
overuse (Figure 4). The results therefore suggest that
medication overuse is unlikely to explain the identified
associations.
The most significant CpG site is at the SH2D5 gene,
which encodes the SH2 Domain Containing 5 protein.
The second strongest associated CpG site is 76 kb
downstream from the nearest gene NPTX2, which
encodes the Neuronal Pentraxin II protein. Both pro-
teins are highly expressed in the adult human brain
(23,24) (Supplemental Figure 1), and DNA methylation
levels at the associated CpG sites are highly correlated
between brain and blood (Table 3 and Figure 2). Both
proteins have presumed roles in regulating synaptic
plasticity. The SH2 Domain Containing 5 protein
regulates synaptic plasticity through the control of
Rac-GTP levels (25). Neuronal Pentraxin II regulates
synaptic plasticity by acting as an inhibitor of excita-
tory synapses, through binding and clustering of gluta-
matergic AMPA receptors. Neuronal Pentraxin II is
induced by neuronal activity, and has an assumed func-
tion in rebalancing excitation-inhibition after periods of
increased synaptic activity (23). Of interest, another of
the top associated CpG markers is related to glutamate
signaling. GRID2 encodes the glutamate receptor d2, an
ionotropic glutamate receptor which is expressed in
several brain regions, with highest expression in the
cerebellum (20,26). Epigenetic alteration of synaptic
plasticity has been previously hypothesized as a pos-
sible mechanism of migraine chronification (6).
Support for this comes from the experimental finding
that synchronous neuronal activity, which also occurs
in cortical spreading depression of the migraine aura
(27), results in DNA methylation changes in brain-
specific genes related to neuronal plasticity (28).
One may envisage that as neuronal activity can cause
epigenetic changes altering synaptic plasticity, migraine
attacks in a feed-forward loop may promote subse-
quent migraine attacks leading to chronification.
Our findings seem to provide at least some support
for a role of synaptic plasticity in headache chronifica-
tion. Regardless, it is far from clear whether such
changes are a cause or consequence of frequent head-
ache attacks. Furthermore, our findings may implicate
that glutamatergic activity is implicated not only in
migraine pathogenesis (29), but also in the transition
from episodic to chronic headache.
When considering the more extensive list of 200
top-ranking CpG sites, there is a statistically significant
enrichment in genes related to several specific func-
tional groups and pathways. The strongest enrichment
was seen for calcium ion binding. Calcium ion bind-
ing and signaling is important in a wide range of
cellular systems, including the synaptic release of
neurotransmitters (30). While this presents a plausible
mechanism for calcium ion imbalance in migraine
pathogenesis, no genetic association to this or other
calcium channels have been found for the common
forms of migraine (31). The second strongest enrich-
ment was found for genes involved in biological cell
adhesion. Cell adhesion molecules have multiple roles
in tissue development and function. In the human brain
they play a major role at synapses, where they control
synaptic morphology and plasticity, and at the neuro-
vascular unit they form the molecular interface between
the vascular and the central nervous system and are
involved in the complex signaling between these sys-
tems (32,33). Lastly, in this study of female subjects,
we found enrichment for genes involved in estrogen
receptor signaling. This corresponds well with lines of
evidence suggesting a role of estrogen in migraine
pathogenesis (34). Estrogen receptor signaling has
also been discussed specifically in relation to possible
epigenetic mechanisms in migraine, since the estrogen
receptors predominantly assert their action through the
epigenetic programming of target genes (6).
Strengths of this study include the genome-wide
assessment of DNA methylation sites, which allowed
us to search for genetic loci associated with headache
chronification without relying on previous hypotheses.
Also, the headache classification used in this study has
been validated by clinical interview. Given the longitu-
dinal design we could determine DNA methylation
levels in both cases and controls at two time points,
before and after the development of chronic headache,
which gave the possibility to detect changes in DNA
methylation levels occurring during the natural course
of the disease.
Our study has clear limitations. Despite a large base-
line population of 51,000 individuals with available
DNA who were characterized with respect to headache,
and a follow-up time of 11 years, only 36 cases fulfilled
inclusion criteria and could be used in the final analysis.
This resulted in limited statistical power, as indicated
by the failure to replicate signals identified in the dis-
covery stage in the smaller replication sample. We
therefore focused our subsequent analyses on the com-
bined dataset of both stages in order to maximize the
power to detect true signals. The loci identified from the
combined analysis aggregate in functionally meaningful
pathways, indicating the presence of true signals.
Nevertheless, the reported associations will require rep-
lication in independent samples, but given our complex
design this will be challenging. This clearly demon-
strates the difficulty of designing studies of epigenetic
changes during the natural course of incident disease,
and suggests that international collaboration is
required to achieve robust sample sizes when using
such a study design. Another limitation was that we
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determined DNA methylation in leucocytes from whole
blood, whereas DNA methylation patterns are to a
considerable extent tissue-specific, so our findings may
not be representative of changes occurring in the more
relevant tissue in headache, in particular the brain (8).
However, for the majority of the top associated mar-
kers, DNA methylation levels in blood correlated well
with DNA methylation levels in one or more brain
regions, suggesting that our design has good potential
to detect DNA methylation relevant to migraine. This
is also in line with previous studies that have found that
DNA methylation patterns in non-affected tissues such
as blood can be of value, even leading to treatment
decisions (35).
A better understanding of the mechanisms underly-
ing headache chronification will be important for
developing better strategies to treat and prevent head-
aches in these severely affected patients. Epigenetic
changes represent modifiable factors, and thereby
offer potential targets for novel drug therapies (5).
Although candidate regions identified in this study
require independent replication and further character-
ization, this is a first step towards understanding epi-
genetic changes occurring in headache chronification.
Article highlights
. The two CpG sites with strongest association to headache chronification were found in relation to genes that
regulate synaptic plasticity.
. Associated CpG sites also showed enrichment for genes involved in calcium ion binding, cell adhesion and
estrogen receptor pathways.
. The results suggest possible mechanisms by which epigenetic DNA methylation may be involved in the
chronification of headache.
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